ReviewFrontiers in oncology2025
MRI management of focal liver lesions: what a beginner cannot fail to know.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advancements in intratumoral therapies for liver tumors.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Magnetic resonance imaging (MRI) is currently recognized as the most suitable diagnostic tool for the detection and characterization of focal liver lesions. The combination of morphological and functional data allows, in different clinical scenarios, high diagnostic performance in characterizing even very small lesions, thereby improving patient management while reducing costs and examination time. Despite this premise, MRI should not be prescribed for all patients with focal liver lesions. Indications must be clearly understood, and the individual characteristics of each patient must be considered. For different clinical scenarios, depending on the presence of extrahepatic malignancy or known liver disease, MRI with contrast agents represents a useful diagnostic tool, although the choice will also depend on operator experience, technology availability, and patient-specific characteristics. A standard protocol should include conventional sequences: T2-weighted (T2W) sequences, T2W sequences with fat suppression (FS), and in-phase and opposed-phase gradient-echo T1 sequences, along with functional sequences. Among functional techniques, diffusion-weighted imaging (DWI) is mandatory, particularly for detecting very small lesions; however, diffusion restriction does not necessarily indicate malignancy. Contrast-enhanced MRI remains the cornerstone of liver MRI, especially for lesion categorization. Contrast agents can be classified as non-specific agents, which distribute into vascular and extracellular extravascular spaces, and specific agents, which are taken up by hepatic cells (Kupffer cells or hepatocytes). The abbreviated protocol concept is based on the premise that, within a shorter examination time, it is possible to acquire the essential information needed for patient management using only selected sequences from a standard protocol. Radiomics has emerged as a promising tool in liver oncology, particularly for evaluating colorectal liver metastases. To fully realize the clinical value of radiomics, it is essential to overcome several methodological hurdles, including the standardization of image acquisition and analysis workflows and rigorous validation across large and diverse patient cohorts. The aim of this review, designed for beginners in liver MRI, is to provide a comprehensive overview of the management of focal liver lesions, with a focus on acquisition protocols (including abbreviated protocols), contrast media, and reporting strategies to ensure accurate lesion characterization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.